Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly EBIT Margin of 10173.74% for Q3 2025, down 879713.0% year-over-year from N/an in Q3 2024, and up 43.78% quarter-over-quarter from 18096.89% in Q2 2025.
Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' EBIT Margin history runs 4 years deep, the most recent figure standing at 10173.74% for Q3 2025.
- In Q3 2025, EBIT Margin fell 879713.0% year-over-year to 10173.74%; the TTM figure through Sep 2025 stood at 4504.27% (down 295031.0% YoY), while the FY2024 annual figure was 1633.74%, up 7093.0% from the prior year.
- EBIT Margin for Q3 2025 stood at 10173.74%, up from 18096.89% in the prior quarter.
- The five-year high for EBIT Margin was 703.67% in Q3 2022, with the low at 18096.89% in Q2 2025.
- The 4-year median for EBIT Margin is 1705.52% (2023), against an average of 3625.17%.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin soared 63438 bps in 2024, then slumped 1690505 bps in 2025.
- Dianthus Therapeutics' EBIT Margin stood at 910.04% in 2022, then plunged by 234 bps to 3041.31% in 2023, then grew by 21 bps to 2406.94% in 2024, then slumped by 323 bps to 10173.74% in 2025.
- Business Quant data shows DNTH's EBIT Margin at 10173.74% in Q3 2025, 18096.89% in Q2 2025, and 2764.75% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,173.74% |
| Jun 30, 2025 | -18,096.89% |
| Mar 31, 2025 | -2,764.75% |
| Dec 31, 2024 | -2,406.94% |
| Sep 30, 2024 | -1,376.61% |
| Jun 30, 2024 | -1,191.84% |
| Mar 31, 2024 | -2,041.65% |
| Dec 31, 2023 | -3,041.31% |
| Sep 30, 2023 | -1,705.52% |
| Jun 30, 2023 | -1,177.60% |
| Mar 31, 2023 | -1,536.60% |
| Dec 31, 2022 | -910.04% |
| Sep 30, 2022 | -703.67% |